The state of the science · 2026

Beyond the diagnosis.

Schizophrenia research is changing. New drug targets, better understanding of the brain, and a clearer picture of what actually helps. Here's what the evidence says—without the breakthrough hype.

Updated 17 November 2026Research-ledAustralian perspective
Explore the research ↓
Abstract neural network illustration with connected glowing nodes, representing brain research
Illustration: connected neural systems, not a diagnostic scan.
2024First US approval of a muscarinic antipsychotic, Cobenfy [1]
~30%Approximate share with treatment-resistant illness [2]
2026New Australasian treatment guidelines and updated clinical reviews [3]
01 / The big picture

A turning point, not a cure.

The most important change in schizophrenia science is the recognition that one pathway—and one type of symptom—cannot explain the entire illness.

Most established antipsychotics directly affect dopamine D2 receptors. They often reduce hallucinations and delusions, but may do less for motivation, pleasure, social withdrawal and cognitive difficulties. New research is probing muscarinic signalling, genetic risk, glutamate-related pathways, learning, and the brain's interacting circuits.

The central distinctionA treatment can be scientifically novel without being more effective, safer for every person, or available in Australia. The strongest evidence still supports combining appropriate medication, psychosocial care, and physical-health monitoring.

Sources: 2026 clinical review · Australasian guidelines · 2025 international guideline

02 / Understanding schizophrenia

Three different problems, often treated as one.

Better-established targets

Positive symptoms

Hallucinations, delusions and disorganised thinking. “Positive” means an experience is added, not that it is beneficial. These tend to respond most clearly to antipsychotic treatment.

Major unmet need

Negative symptoms

Reduced motivation, enjoyment, expression, speech or social engagement. Depression, medication sedation and environmental factors can resemble negative symptoms, making assessment important.

Major unmet need

Cognitive difficulties

Problems with working memory, attention, processing speed and executive function. These can persist even when psychosis is controlled.

Often overlooked

Physical health

Weight, blood glucose, lipids, cardiovascular health, sleep, smoking and movement side effects affect everyday wellbeing and long-term health.

Negative symptoms are not automatically laziness or lack of willpower. A good assessment distinguishes primary symptoms from medication effects, depression, sleep disorders and isolation. [2]

03 / What works today

The established treatment toolkit.

There is no universally best antipsychotic. Choice depends on previous response, side effects, other conditions, interactions, preferences and formulation. The 2026 Australian and New Zealand guidance places particular weight on cardiometabolic effects and shared decisions. [3]

ApproachWhat it can doImportant limitations
Antipsychotic medication
e.g. aripiprazole, risperidone, paliperidone, olanzapine, lurasidone
Can reduce positive symptoms and prevent relapse.Effects on cognition and primary negative symptoms are often limited; side effects differ substantially.
Long-acting injectables
including paliperidone and aripiprazole formulations
Offer reliable dosing and can reduce relapse or hospitalisation for some people.Do not remove intrinsic medication side effects; availability and intervals vary by product.
ClozapineKey evidence-based option when adequate trials of other antipsychotics have not worked.Requires specialist supervision and blood monitoring; adverse effects can be serious.
CBT for psychosis, education and psychosocial supportHelps reduce distress, develop coping strategies and improve functioning.Usually complements medication rather than replacing it.
Cognitive remediation / exerciseTarget cognitive skills and everyday functioning; exercise supports physical and mental health.Benefits vary; access and sustained participation matter.
Do not stop antipsychotics abruptlyStopping or reducing medication without a plan can trigger relapse or withdrawal-related problems. Review risks and alternatives with your treating team.

Sources: Australasian GRADE · INTEGRATE · BMJ review

04 / Medication developments

Drugs moving beyond dopamine.

US-approved · 2024

Cobenfy (xanomeline + trospium)

What is different: xanomeline activates central muscarinic M1/M4 receptors rather than directly blocking D2 receptors. Trospium helps limit peripheral cholinergic effects. US trials demonstrated symptom improvement against placebo.

Potential benefit: less dopamine-blockade-associated movement and metabolic burden in short-term trials. Trade-offs: nausea, vomiting, constipation, dyspepsia, twice-daily administration and dosing relative to meals. Longer-term retention and direct comparison with standard drugs remain important questions.

Australian availability: a September 2026 Australian clinical review reported that no TGA registration application had been submitted as of March 2026. That is not confirmation of its regulatory status today; verify the current ARTG before publishing any present-tense availability claim.

FDA approval · September 2026 Australian review · November 2026 systematic review

Phase 3 underway

Roluperidone

Designed for prominent negative symptoms, a particularly difficult treatment target. After an FDA rejection in 2024, an additional confirmatory Phase 3 trial was underway in November 2026. Results were projected for the second half of 2027; success is not guaranteed. [7]

Investigational

M4-selective medicines

Drugs aiming for greater muscarinic receptor selectivity, including candidates such as NBI-1117568, are being studied. Early signals are not equivalent to successful Phase 3 trials, approval, or proven long-term advantage. [8]

Other directions include dopamine-serotonin modulators, glutamate-system approaches, and compounds intended specifically for cognitive or negative symptoms. Many candidates never complete development. [8]

05 / Treatment quality

Managing the cost of treatment.

The goal is not merely fewer psychotic symptoms. It is a workable life, with attention to fatigue, movement disorders, sexual side effects, weight, glucose, sleep and quality of life.

Measure metabolic risk from the start

Track weight, waist where appropriate, blood pressure, glucose or HbA1c, and lipids with clinical guidance. Lifestyle strategies matter throughout treatment.

Consider evidence-based weight management

Recent Australasian guidance strongly recommends adjunctive metformin for antipsychotic-associated weight gain and suggests GLP-1 receptor agonists for selected cases. These require individual medical assessment.

Ask whether side effects resemble illness symptoms

Akathisia can look like agitation; sedation can look like poor motivation; elevated prolactin can affect sexual function. These distinctions change management.

Review treatment response methodically

Assess dose, duration, adherence, substance use, medical contributors, and symptom profile before concluding that a medication has failed.

Source: Australasian GRADE guidelines (2026)

06 / New discoveries

What the biology is revealing.

Genetic discovery

A polygenic condition

Large genome-wide studies implicate many genetic regions, each often contributing a small share of risk. A 2025 cross-ancestry analysis identified 61 previously unreported loci and proposed possible drug targets. This does not yet yield a reliable diagnostic genetic test or a personalised prescription. [9]

Mechanisms under study

Synapses and circuits

Scientists are investigating how glutamate signalling, inhibitory circuits, synaptic development and network coordination relate to symptoms. The biology is heterogeneous, not a single chemical imbalance. [2]

Longer-term opportunity

Precision psychiatry

Researchers hope that combined clinical, biological and cognitive measures will predict treatment response. Reliable, widely validated tools to choose one antipsychotic for an individual are not yet routine care. [2]

Better outcomes research

Function beyond symptom scores

Newer work looks beyond hallucination and delusion ratings to social functioning, motivation, cognition, relapse, physical health and patients' own goals. [4]

The next advance may be a better match between a person and a treatment, not a single drug that works for everyone.
07 / More than medication

Psychological and brain-based approaches.

Guideline-supported

CBT for psychosis

Targets distress, interpretations, coping and goals. It does not require arguing someone out of their experiences. Australasian guidance recommends offering CBT for psychosis. [3]

Guideline-supported

Cognitive remediation

Structured practice and strategy training that can address cognitive difficulties, especially when paired with real-world rehabilitation and support. [3]

Emerging evidence

AVATAR therapy

A therapist-guided approach to distressing voices, using a digital representation of a voice. A 2026 evidence synthesis found promising results, though access, replication and implementation remain challenges. [10]

Mixed evidence

Magnetic brain stimulation

Some analyses suggest benefits of particular stimulation protocols for voices; another 2026 review found no consistent overall advantage over sham in treatment-resistant illness. It is not a universal proven solution. [11] [12]

08 / What comes next

The research horizon.

These are directions to watch, not predicted cures. Dates for future results are estimates and may change.

FrontierWhy researchers careWhat remains unproven
Muscarinic-targeted medicinesA non-D2 route to improving psychosis, with potentially different side-effect profiles.Head-to-head effectiveness, long-term outcomes, wider availability.
Negative-symptom medicationCould address low motivation and expression, often poorly treated today.Whether large confirmatory trials show meaningful real-world benefit.
Cognitive treatmentsMemory and executive function are central to work and independence.A reproducible drug effect on cognition and daily functioning.
Biomarkers and patient subtypesCould reduce trial-and-error prescribing.Validated, affordable tools that improve decisions beyond standard clinical assessment.
Digital therapies and brain stimulationMay help targeted symptoms such as distressing voices.Which protocols work for whom, durability, accessibility and independent replication.
09 / Reality checks

Not every promising idea survives testing.

Phase 3 failure

Iclepertin

A glycine transporter-1 inhibitor intended to improve cognition. Three major CONNEX Phase 3 trials did not demonstrate the hoped-for benefit, a significant setback for cognitive drug development. [13]

No superiority established

Cobenfy comparison gap

Its efficacy against placebo is real. A November 2026 systematic review found no direct randomised head-to-head trials establishing overall superiority to established antipsychotics. [6]

Research is not the same as clinical readiness.Animal studies, small trials, press releases, regulatory approval and treatment guidelines are different levels of evidence. A drug company's projected milestone is not a demonstrated outcome.
10 / Practical perspective

What this means in Australia.

For an Australian reader, research results do not automatically translate to a locally approved, affordable or accessible treatment. Confirm whether a medicine is included on the Australian Register of Therapeutic Goods and, separately, the Pharmaceutical Benefits Scheme.

The 2026 Australia–New Zealand guideline is a particularly useful guide to current care. It emphasises appropriate antipsychotic selection, offering long-acting formulations, prompt clozapine for treatment resistance, CBT for psychosis, cognitive remediation, exercise and early metabolic risk management. [3]

Questions worth taking to a psychiatrist

Which symptoms are being targeted?

Psychosis, motivation, cognition, anxiety, sleep and adverse effects may need different strategies.

Is the current response adequate?

What would count as worthwhile improvement, and when should treatment be re-evaluated?

Are side effects being measured?

Ask about metabolic blood tests, movement symptoms, sexual function and daytime fatigue.

What non-drug supports are accessible?

Psychosis-focused therapy, cognitive remediation, peer support, psychosocial rehabilitation and physical activity programmes may improve day-to-day life.

A realistic reason for hopeProgress does not depend on a future miracle drug. Better use of effective existing treatments, physical-health care, rehabilitation and targeted new medicines can each improve outcomes.

For urgent mental health emergencies in Australia, call 000. For non-emergency support, discuss your situation with your GP, psychiatrist or local mental health service.

11 / References

Read the original research.

Sources favour regulators, peer-reviewed research and professional guidelines. Industry statements are identified as such. This page was researched on 17 November 2026. It is a dated snapshot, not a continuously updated medical resource.

  1. 1 · US FDA — Approval of CobenfyFDA · 26 Sep 2024 · Regulatory primary sourceView FDA announcement
  2. 2 · Schizophrenia: advances in pathophysiology, management, and precision medicineBMJ · 2026 · Broad peer-reviewed clinical reviewRead review
  3. 3 · Australian and New Zealand GRADE guidelines for schizophreniaAustralian & New Zealand Journal of Psychiatry · 2026 · Clinical guidelineRead clinical recommendations
  4. 4 · INTEGRATE: international guidelines for algorithmic treatmentThe Lancet Psychiatry / RANZCP · 2025 · International guidelineOpen RANZCP guide
  5. 5 · Cobenfy: an Australian clinical updateAustralasian Psychiatry · Sep 2026 · Australian regulatory/clinical contextRead clinical update
  6. 6 · Xanomeline/trospium: is it revolutionary?Innovations in Clinical Neuroscience · Nov 2026 · Systematic reviewRead systematic review
  7. 7 · Roluperidone Phase 3 development updateMinerva Neurosciences · 6 Nov 2026 · Company statement, not efficacy evidenceView development update
  8. 8 · New pharmacological approaches after iclepertinCNS Drugs · 2026 · Research pipeline reviewRead pipeline analysis
  9. 9 · Gene-level analysis and potential therapeutic targetsNature Human Behaviour · Jan 2025 · Genome-wide studyRead genetic study
  10. 10 · Non-pharmacological treatments for auditory hallucinations2026 systematic review/meta-analysis · AVATAR therapy, CBT, stimulationRead review
  11. 11 · rTMS for treatment-resistant schizophreniaFrontiers in Psychiatry · Jul 2026 · Systematic review with null pooled resultsRead review
  12. 12 · Non-invasive brain stimulation network meta-analysis2026 · Alternative synthesis reporting effects for certain stimulation protocolsRead meta-analysis
  13. 13 · Iclepertin CONNEX programme, three Phase 3 trialsThe Lancet Psychiatry · Dec 2025 · Randomised trial programmeRead Phase 3 results

↑